Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors

References

• Aithal GP, Day CP, Leathart JB, Daly AK. 2000. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 10:511–518.
   PubMedGoogle Scholar
• Ambrosone CB, Sweeney C, Coles BF, Thompson PA, Mcclure GY, Korourian S, et al. 2001. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Research 61:7130–7135.
   PubMed Web of Science ®Google Scholar
• Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. 2003. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environmental and Molecular Mutagenesis 42:299–305.
   PubMed Web of Science ®Google Scholar
• Amirimani B, Walker AH, Weber BL, Rebbeck TR. 1999. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. Jnci Journal of the National Cancer Institute 91:1588–1590.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Cameron DA. 2011. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. Journal of Clinical Endocrinology and Metabolism. 96:1336–1343.
   PubMed Web of Science ®Google Scholar
• Anon, American Cancer Society. 2014. Cancer treatment and survivorship facts & figures 2014–2015. Atlanta: American Cancer Society.
   Google Scholar
• Bines J, Oleske DM, Cobleigh MA. 1996. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 14:1718–1729.
   PubMed Web of Science ®Google Scholar
• Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, et al. 1992. Early menopause in long-term survivors of cancer during adolescence. American Journal of Obstetrics and Gynecology 166:788–793.
   PubMed Web of Science ®Google Scholar
• Choi JY, Nowell SA, Blanco JG, Ambrosone CB. 2006. The role of genetic variability in drug metabolism pathways in breast cancer prognosis. Pharmacogenomics 7:613–624.
   PubMed Web of Science ®Google Scholar
• De Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. 1994. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. The Journal of Biological Chemistry 269:15419–15422.
   PubMed Web of Science ®Google Scholar
• Demichele A, Gimotty P, Botbyl J, Aplenc R, Colligon T, Foulkes AS, Rebbeck TR. 2007. In response to “Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort”. Journal of Clinical Oncology 25:5675–5677.
   PubMed Web of Science ®Google Scholar
• Dirven HA, Van Ommen B, Van Bladeren PJ. 1994. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Research 54:6215–6220.
   PubMed Web of Science ®Google Scholar
• Dirven HA, Venekamp JC, Van Ommen B, Van Bladeren PJ. 1994b. The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy. Chemico-Biological Interactions. 93:185–196.
   PubMed Web of Science ®Google Scholar
• Dolleman M, Depmann M, Eijkemans MJ, Heimensem J, Broer SL, Van Der Stroom EM, et al. 2014. Anti-Mullerian hormone is a more accurate predictor of individual time to menopause than mother’s age at menopause. Human Reproduction 29:584–591.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. 2000. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. Journal of the National Cancer Institute 92:1054–1064.
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. 1999. Risk of menopause during the first year after breast cancer diagnosis. Journal of Clinical Oncology 17:2365–2370.
   PubMed Web of Science ®Google Scholar
• Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, et al. 2010. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Research 12:R26.
   PubMed Web of Science ®Google Scholar
• Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, De Villiers TJ, for the STRAW + 10 Collaborative Group. 2012. Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology and Metabolism. 97:1159–1168.
   PubMed Web of Science ®Google Scholar
• Hayes JD, Pulford DJ. 1995. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Critical Reviews in Biochemistry and Molecular Biology. 30:445–600.
   PubMed Web of Science ®Google Scholar
• Jordan VC. 2003. Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery 2:205–213.
   PubMed Web of Science ®Google Scholar
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 27:383–391.
   PubMed Web of Science ®Google Scholar
• Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, et al. 2001. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399–415.
   PubMedGoogle Scholar
• Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. 2004. Web-based survey of fertility issues in young women with breast cancer. Journal of Clinical Oncology 22:4174–4183.
   PubMed Web of Science ®Google Scholar
• Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, Sukumvanich P. 2006. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. Journal of Clinical Oncology 24:1045–1051.
   PubMed Web of Science ®Google Scholar
• Pinto N, Ludeman SM, Dolan ME. 2009. Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 10:1897–1903.
   PubMed Web of Science ®Google Scholar
• Scripture CD, Sparreboom A, Figg WD. 2005. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncology. 6:780–789.
   PubMed Web of Science ®Google Scholar
• Sharda SV, Gulati S, Tripathi G, Jafar T, Kumar A, Sharma RK, Agrawal S. 2008. Do glutathione-S-transferase polymorphisms influence response to intravenous cyclophosphamide therapy in idiopathic nephrotic syndrome? Pediatric Nephrology 23:2001–2006.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2019. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians 69:7–34.
   PubMed Web of Science ®Google Scholar
• Su HI, Sammel MD, Velders L, Horn M, Stankiewicz C, Matro J, et al. 2010. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors. Fertility and Sterility 94:645–654.
   PubMed Web of Science ®Google Scholar
• Sunderland MC, Osborne CK. 1991. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. Journal of Clinical Oncology 9:1283–1297.
   PubMed Web of Science ®Google Scholar
• Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF, Coles BF. 2003. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. International Journal of Cancer 103:810–814.
   PubMed Web of Science ®Google Scholar
• Sweeney C, Farrow DC, Schwartz SM, Eaton DL, Checkoway H, Vaughan TL. 2000. Glutathione S-transferase M1, T1, and P1 polymorphisms as risk factors for renal cell carcinoma: a case-control study. Cancer Epidemiology, Biomarkers and Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 9:449–454.
   Google Scholar
• Sweeney C, Mcclure GY, Fares MY, Stone A, Coles BF, Thompson PA, et al. 2000. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Research 60:5621–5624.
   PubMed Web of Science ®Google Scholar
• Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE, et al. 2004. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis and Rheumatism 50:2202–2210.
   PubMed Web of Science ®Google Scholar
• Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K, et al. 2005. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. The Pharmacogenomics Journal 5:365–373.
   PubMed Web of Science ®Google Scholar
• Van Schaik RH. 2008. CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resistance Updates 11:77–98.
   PubMed Web of Science ®Google Scholar
• Walshe JM, Denduluri N, Swain SM. 2006. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 24:5769–5779.
   PubMed Web of Science ®Google Scholar
• Warne GL, Fairley KF, Hobbs JB, Martin FI. 1973. Cyclophosphamide-induced ovarian failure. New England Journal of Medicine 289:1159–1162.
   PubMed Web of Science ®Google Scholar
• Zhong S, Huang M, Yang X, Liang L, Wang Y, Romkes M, et al. 2006. Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. British Journal of Clinical Pharmacology 62:457–472.
   PubMed Web of Science ®Google Scholar